<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376296</url>
  </required_header>
  <id_info>
    <org_study_id>SBI-DTX-004</org_study_id>
    <nct_id>NCT02376296</nct_id>
  </id_info>
  <brief_title>Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients</brief_title>
  <official_title>Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saladax Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UPMC CancerCenter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saladax Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this observational study, blood samples for pharmacokinetic (PK) testing will be collected
      from subjects with metastatic prostate cancer during their treatment with docetaxel. Plasma
      levels of docetaxel will be determined, and the subjects docetaxel exposure levels,
      determined as an area under the curve (AUC), will be retrospectively correlated with reports
      of toxicity, tumor response, quality of life, time to disease progression and overall
      survival to provide guidance on what the appropriate target range for docetaxel exposure
      should be for metastatic prostate cancer subjects receiving docetaxel therapy for their
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variability of docetaxel exposure</measure>
    <time_frame>Up to 6 months after the initiation of docetaxel therapy</time_frame>
    <description>Blood will be drawn during the first six cycles of docetaxel therapy to determine the variability of docetaxel exposure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Docetaxel treatment related toxicities</measure>
    <time_frame>Up to 7 months after the initiation of docetaxel therapy</time_frame>
    <description>Determine the relationship between docetaxel plasma concentrations (i.e. exposure level) and the incidence of docetaxel related toxicities for identification of an optimal target docetaxel exposure range.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of growth factor usage</measure>
    <time_frame>Up to 7 months after the initiation of docetaxel therapy</time_frame>
    <description>Determine relationship (if any) between growth factor usage and docetaxel exposure levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days hospitalized for treatment of docetaxel related toxicities</measure>
    <time_frame>Up to 7 months after the initiation of docetaxel therapy</time_frame>
    <description>Determine relationship (if any) between number of day hospitalized due to treatment related toxicities and docetaxel exposure levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to prostate specific antigen (PSA) progression</measure>
    <time_frame>Up to 24 months after the initiation of docetaxel therapy</time_frame>
    <description>Determine relationship (if any) between the time to PSA progression and docetaxel exposure levels obtained during the first 6 cycles of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as determined by imaging</measure>
    <time_frame>Up to 7 months after the initiation of docetaxel therapy</time_frame>
    <description>Determine relationship (if any) between the tumor response as determined by imaging and docetaxel exposure levels obtained during the first 6 cycles of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>Up to 6 months after the initiation of docetaxel therapy</time_frame>
    <description>Determine relationship between changes in the quality of life (as measured using the FACT-P Questionnaire) and docetaxel exposure levels obtained during the first 6 cycles of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 months after the initiation of docatexel therapy</time_frame>
    <description>Determine relationship between overall survival and docetaxel exposure levels obtained during the first 6 cycles of treatment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>hormone naïve</arm_group_label>
    <description>Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>castrate resistant</arm_group_label>
    <description>Subjects with castrate resistant prostate cancer (CRPC) [defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>3-weekly docetaxel therapy (starting dose of 75 mg/m2)</description>
    <arm_group_label>hormone naïve</arm_group_label>
    <arm_group_label>castrate resistant</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draws</intervention_name>
    <description>Blood draws for determination of docetaxel plasma levels and exposure (AUC)</description>
    <arm_group_label>hormone naïve</arm_group_label>
    <arm_group_label>castrate resistant</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Metastatic prostate cancer patients, either newly diagnosed or castrate resistant, who are
        about to start treatment with a 3-weekly docetaxel treatment regimen (starting dose of 75
        mg/m2) within the University of Pittsburgh Medical Center (UPMC) Cancer Center network.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.

          -  Male subjects 18 years of age or older.

          -  About to start a new line of treatment with docetaxel (75 mg/m2) in combination with
             prednisone.

          -  All subjects must be informed of the investigational nature of this study and be
             willing to provide written informed consent in accordance with Institutional
             guidelines and good clinical practices (GCP) indicating that they understand the
             purpose of and procedures required for the study and are willing to participate in the
             study prior to the beginning of specific study procedures.

          -  Prior surgical castration or concurrent use of an agent for chemical castration with a
             serum testosterone level &lt; 50 ng/dL.

          -  Subjects with hormone naïve metastatic prostate cancer, must have high-volume disease,
             defined as extra-nodal visceral disease or bone metastases with at least 4 bone
             lesions (one being outside of the vertebral column or pelvis).

          -  Subjects with hormone naïve high-volume metastatic prostate adenocarcinoma must have
             been on androgen deprivation therapy (including luteinizing hormone-releasing hormone
             (LHRH) agonist therapy, LHRH antagonist therapy, or surgical castration) for less than
             120 days prior to starting docetaxel therapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  For subjects with castrate resistant prostate cancer (CRPC), at least four weeks
             elapsed between withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide)
             and initiation of docetaxel therapy.

          -  For subjects with CRPC, at least four weeks elapsed between last administration of
             Abiraterone (Zytiga®) or Enzalutamide (Xtandi®) and initiation of docetaxel therapy.

          -  At least four weeks elapsed between prior surgery or prior radiotherapy and initiation
             of docetaxel therapy.

          -  Radiograph-documented evidence of soft tissue or bony metastatic disease.

          -  Must have adequate hematologic, hepatic and renal function as defined below:

          -  Hematologic (minimal values): Absolute neutrophil count ≥ 1,500/mm3; Hemoglobin ≥ 10.0
             g/dl; Platelet count ≥ 75,000/mm3

          -  Hepatic Function: Total Bilirubin ≤ 1.5 x institutional upper limit of normal (ULN);
             asparate transaminase (AST) and alanine transaminase (ALT) &lt; 2 x institutional ULN

          -  Suitable venous access and healthy enough (as determined by the treating physician) to
             provide whole blood sample.

        Exclusion Criteria:

          -  Any condition / concomitant disease not allowing chemotherapy with docetaxel,
             prednisone or required premedication for the treatment regimen.

          -  Serious concurrent disorders (active infection requiring intravenous antibiotics,
             unstable angina, uncompensated congestive heart failure (CHF), or hepatic failure)
             that, in the opinion of the investigator, would prevent the use of docetaxel and/or
             compromise the subject's ability to provide whole blood samples for participation in
             the study.

          -  Concurrent use of any non-FDA approved (i.e. investigational or experimental)
             anticancer agent(s) or within four (4) weeks of enrolling on the study.

          -  Pre-existing neuropathy ≥ grade 2 per the National Cancer Institute Common Terminology
             Criteria for Adverse Events (NCI CTCAE) version 4.

          -  Individuals with known seropositivity for human immunodeficiency virus (HIV),
             hepatitis C virus, hepatitis B surface antigen, or syphilis.

          -  Unwilling or unable to follow protocol requirements or to provide informed consent.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul A Parikh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC CancerCenter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Miller, BS</last_name>
    <phone>484-547-0540</phone>
    <email>cmiller@saladax.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC CancerCenter - Beaver</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Flanagan</last_name>
      <phone>724-371-3852</phone>
      <email>flanagankd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>William Ferri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stewart Lancaster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace R Tarabay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Upper St. Clair</name>
      <address>
        <city>Bethel Park</city>
        <state>Pennsylvania</state>
        <zip>15102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Pfrimmer</last_name>
      <phone>412-831-7096</phone>
      <email>pfrimmerra@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Fierro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent E Reyes, Jr., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert VanderWeele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Volkin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Horizon</name>
      <address>
        <city>Farrell</city>
        <state>Pennsylvania</state>
        <zip>16121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Thompson</last_name>
      <phone>814-676-7881</phone>
      <email>thompsonk15@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>William Spielvogel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Cancer Center - Oakbrook</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <zip>15601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trout</last_name>
      <phone>724-834-1463</phone>
      <phone_ext>119</phone_ext>
      <email>troutdl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hyoung Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Waas, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Cancer Center</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <zip>15601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Alfery</last_name>
      <phone>724-838-5693</phone>
      <email>alferyas@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Terry Evans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauri Kiefer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajesh Sehgal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Sulecki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franklin Viverette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Thompson</last_name>
      <phone>814-676-7881</phone>
      <email>thompsonk15@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Edgardo Lob, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Indiana</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Sosko</last_name>
      <phone>814-534-2887</phone>
      <email>soskoj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Gopala Ramineni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Voloshin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter at John P. Murtha Regional Cancer Center</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Sosko</last_name>
      <phone>814-533-0106</phone>
      <email>soskoj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Rashid Awan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Voloshin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Mckeesport</name>
      <address>
        <city>McKeesport</city>
        <state>Pennsylvania</state>
        <zip>15132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Doyle</last_name>
      <phone>412-653-8103</phone>
      <email>doylea2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Bierenbaum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Kane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Monroeville</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Zaspel</last_name>
      <phone>412-374-1441</phone>
      <email>zaspma@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hyoung Kim, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Lech, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dhaval Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Morcos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajesh Sehgal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Medical Oncology - Mount Pleasant</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Pennsylvania</state>
        <zip>15666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trout</last_name>
      <phone>724-834-1463</phone>
      <phone_ext>119</phone_ext>
      <email>troutdl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hyoung Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John P Morcos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - New Castle</name>
      <address>
        <city>New Castle</city>
        <state>Pennsylvania</state>
        <zip>16105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Flanagan</last_name>
      <phone>724-658-0853</phone>
      <phone_ext>107</phone_ext>
      <email>flanagankd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sheryl Simon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Spielvogel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - St. Margaret</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Van Every</last_name>
      <phone>412-781-3744</phone>
      <email>vaneverycc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Ellis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Georgiadis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongmei Liang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Sun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Flaherty</last_name>
      <phone>412-623-8962</phone>
      <email>schnelbachb@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristyn Miller</last_name>
      <phone>412-647-8475</phone>
      <email>millerkm3@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leonard J Appleman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lanie K Francis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David M Friedland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barry C Lembesky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanley M Marks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James P Ohr, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul A Parikh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel P Petro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John C Rhee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald G Stroller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Passavant HOA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jackson</last_name>
      <phone>412-748-6027</phone>
      <email>jacksonm12@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Osborn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Passavant OHA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jackson</last_name>
      <phone>412-748-6027</phone>
      <email>jacksonm12@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Crandall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Gluckman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian McLaughlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiran Rajasenan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Northwest</name>
      <address>
        <city>Seneca</city>
        <state>Pennsylvania</state>
        <zip>16346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Thompson</last_name>
      <phone>814-676-7881</phone>
      <email>thompsonk15@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Cindylou Connell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donna Puleio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Uniontown</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Strauser</last_name>
      <phone>724-439-8950</phone>
      <phone_ext>126</phone_ext>
      <email>strauserhj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Afaq Ahmad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lijun Dai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sajid M Peracha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Washington</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Goddard</last_name>
      <phone>724-223-3816</phone>
      <email>goddardea@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Kane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nitin Kapoor, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis Megaludis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter - Jefferson</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Doyle</last_name>
      <phone>412-653-8103</phone>
      <email>doylea2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Earle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Laman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic prostate cancer</keyword>
  <keyword>castrate resistant prostate cancer</keyword>
  <keyword>CRPC</keyword>
  <keyword>hormone sensitive prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

